Skip to main content

Spotlight: Manifest Technologies


Spotlight: Manifest Technologies

Faculty Founders

Alan Anticevic, PhD, Glenn H. Greenberg Associate Professor of Psychiatry and Associate Professor of Psychology; Director, Division of Neurocognition, Neurocomputation, and Neurogenetics (N3), Psychiatry

John D Murray, PhD, Associate Professor Adjunct of Psychiatry


License signed in 2023

About the Venture

Manifest Technologies, a Yale spinout that is accelerating Central Nervous System (CNS) drug development through a precision neuroimaging platform, signed a license. Current cost and efficiency barriers in CNS clinical trials result in an extremely low 4% CNS drug approval rate. With animal-to-human neural targeting mapping and precise patient selection, Manifest Technologies’ platform de-risks CNS drug R&D and can substantially increase the probability of bringing existing and novel CNS therapeutics to market.   

I want you to imagine a future in which every person who has a central nervous system disease can get neuro-informed precise drug targeting—we’re here to solve that.  Alan Anticevic, Co-Founder & CEO, Manifest Technologies